Tandem Diabetes Care's Total Assets for the quarter that ended in Mar. 2026 was MXN20,799 Mil.
Warning Sign:
If a company builds assets at 21% a year, faster than its revenue growth rate of 11.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Tandem Diabetes Care's average Total Assets Growth Rate was 5.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 10.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 21.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 31.60% per year.
During the past 13 years, Tandem Diabetes Care's highest 3-Year average Total Assets Growth Rate was 94.50%. The lowest was 10.50%. And the median was 30.60%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Tandem Diabetes Care's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Tandem Diabetes Care Total Assets Related Terms
Tandem Diabetes Care Total Assets Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Tandem Diabetes Care's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (MEX:TNDM) has a Total Assets of MXN20,799 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Total Assets too high?
Tandem Diabetes Care's current Total Assets is MXN20,799 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Total Assets compare to CNMD and AORT?
Tandem Diabetes Care's Total Assets of MXN20,799 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Total Assets is MXN20,799 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Tandem Diabetes Care (MEX:TNDM) has a current Total Assets of MXN20,799 Mil. The stock's GF Value™ is MXN1,446.01, compared to a current price of MXN745.00 — trading 48.5% below its estimated fair value. The current Total Assets is MXN20,799 Mil. Tandem Diabetes Care's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Tandem Diabetes Care (MEX:TNDM), the current Total Assets is MXN20,799 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (MEX:TNDM) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of MXN745.00 is trading 48.5% below its estimated GF Value™ of MXN1,446.01.
Key valuation signals for MEX:TNDM:
Total Assets: MXN20,799 Mil
GF Value™: MXN1,446.01 vs. price of MXN745.00 (48.5% below fair value)
No single metric tells the full story. See the MEX:TNDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
66GF Score
Get the complete analysis for MEX:TNDM
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TNDM has been successfully added to your 
